DexCom (DXCM) Stock
Key stats
- Market cap
- $29.62B
- Price / Earnings ratio
- 29.9x
- EPS (TTM)
- $2.59
- Volume
- Loading
- 52-week high
- $92.59
- 52-week low
- $54.20
- EPS vs analyst estimate
- +7.0%Q3 FY25 · $0.61 vs $0.57
Source: third-party data provider, as of November 10, 2026
EPS estimate: analyst consensus
Compare with DXCM
Recent news

DexCom to Launch 15-Day G7 CGM System in Canada This November
DexCom to Launch 15-Day G7 CGM System in Canada This November
DXCM

Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
DXCM

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DXCM

What DexCom (DXCM) Said on Its Q3 Earnings Call
What DexCom (DXCM) Said on Its Q3 Earnings Call
DXCM
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 46.12
- MACD 12/26/9
- -0.71
- EMA 9 of MACD
- -0.92
- MACD histogram
- 0.21
- SMA 50
- $85.01
- Price below SMA 50
- EMA 50
- $83.49
- Price below EMA 50
- SMA 200
- $74.93
- Price above SMA 200
- EMA 200
- $75.87
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.67 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

DexCom to Launch 15-Day G7 CGM System in Canada This November
DexCom to Launch 15-Day G7 CGM System in Canada This November
DXCM

Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
DXCM

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DXCM

What DexCom (DXCM) Said on Its Q3 Earnings Call
What DexCom (DXCM) Said on Its Q3 Earnings Call
DXCM

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
DXCM

Diabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales Guide
Diabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales Guide
DXCM

Dexcom Reports Third Quarter 2026 Financial Results
Dexcom Reports Third Quarter 2026 Financial Results
DXCM

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
DXCM

DexCom Gears Up to Report Q3 Results: How to Play the Stock?
DexCom Gears Up to Report Q3 Results: How to Play the Stock?
DXCM

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
DXCM
News tone: automated (AI) classification of the article's content, not a price prediction.
About DexCom
Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Jacob Steven Leach | President, CEO & Director | 1978 |
| Mr. Kevin Ronald Sayer | Executive Chairman of the Board | 1958 |
| Mr. Jereme M. Sylvain CPA | Executive VP, CFO, COO & Chief Accounting Officer | 1980 |
| Mr. Michael Jon Brown J.D. | Executive VP, Chief Legal & Compliance Officer | 1970 |
| Ms. Sadie M. Stern | Executive VP, Chief People & Culture Officer | 1975 |
| Mr. Jon Coleman | Executive VP & Chief Commercial Officer | 1964 |
| Mr. Peter Simpson | Executive VP & CTO | — |
| Mr. Sean Christensen | Vice President of Finance and Investor Relations | — |
| Mr. Matthew Dolan | Executive Vice President of Strategy & Corporate Development | 1981 |
| Keri Leone | Senior Director of Global Medical Science & Education | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 10, 2026
Technical indicators
- RSI 14
- 46.12
- MACD 12/26/9
- -0.71
- EMA 9 of MACD
- -0.92
- MACD histogram
- 0.21
- SMA 50
- $85.01
- Price below SMA 50
- EMA 50
- $83.49
- Price below EMA 50
- SMA 200
- $74.93
- Price above SMA 200
- EMA 200
- $75.87
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 9, 2026. Technical data, not a recommendation.
Analyst views
9 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $85.00
- Average
- $100.00
- High
- $120.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -9.3 | -2.1 | ||||||||||
| 2022 | -17.3 | -4.9 | +25.3 | -23.1 | -26.8 | +5.0 | +5.7 | -1.9 | -3.1 | +42.1 | -2.3 | -4.1 |
| 2023 | -6.7 | +3.1 | +4.9 | +5.3 | -1.0 | +7.5 | -1.9 | -17.2 | -8.4 | -6.0 | +22.7 | +6.4 |
| 2024 | -1.4 | -6.1 | +13.9 | -7.6 | -5.6 | -1.6 | -39.5 | -1.4 | -7.4 | +6.8 | +10.9 | -1.9 |
| 2025 | +10.6 | +1.5 | -20.6 | +6.0 | +22.1 | +2.1 | -3.4 | -5.0 | -9.4 | -11.9 | +5.0 | +4.5 |
| 2026 | +9.8 | +1.2 | -14.9 | -4.5 | +20.2 | -10.0 | +21.2 | +4.3 | -4.3 | -4.6 | -6.3 |



